Iovance Biotherapeutics (IOVA) Change in Receivables (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Change in Receivables for 4 consecutive years, with -$690000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables fell 143.18% year-over-year to -$690000.0; the TTM figure through Mar 2026 stood at $10.8 million (down 84.7% YoY), while the FY2025 annual figure was $13.1 million, down 81.05% from the prior year.
• Change in Receivables fell to -$690000.0 in Q1 2026 per IOVA's latest filing, from $15.7 million in the prior quarter.
• Across five years, Change in Receivables topped out at $31.4 million in Q2 2024 and bottomed at -$11.0 million in Q2 2025.
• Historically, Change in Receivables has averaged $6.8 million across 4 years, with a median of $873500.0 in 2023.
• Annual changes were most pronounced in 2024 — Change in Receivables surged 94960.61% — and 2026, when it tumbled 143.18%.
• Iovance Biotherapeutics' Change in Receivables stood at $149000.0 in 2023, then surged by 9008.72% to $13.6 million in 2024, then increased by 15.58% to $15.7 million in 2025, then tumbled by 104.4% to -$690000.0 in 2026.
• Business Quant data shows IOVA's Change in Receivables at -$690000.0 in Q1 2026, $15.7 million in Q4 2025, and $6.8 million in Q3 2025.